<DOC>
	<DOCNO>NCT01151046</DOCNO>
	<brief_summary>To determine whether combination MM-121 + Exemestane ER+ and/or PR+ breast cancer patient effective Exemestane alone</brief_summary>
	<brief_title>Trial Exemestane +/- MM-121 Postmenopausal Women With Locally Advanced Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer</brief_title>
	<detailed_description>The study double-blind , randomize Phase 2 trial Exemestane +/- MM-121 . The trial design demonstrate whether MM-121 + Exemestane effective Exemestane alone ER+ and/or PR+ Her2 negative breast cancer patient fail first-line anti-estrogen therapy locally advance metastatic setting patient progress ( within 6 month complete ) adjuvant treatment non-steroidal aromatase inhibitor ( AI ) and/or tamoxifen . Patients treat radiologic clinical progression disease document . Local radiologist and/or PI assessment accept .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Locally advanced metastatic breast cancer Histologically cytologically confirm ER+ and/or PgR+ Her2 negative breast cancer â‰¥ 18 year age Received prior treatment exemestane Extensive visceral disease ( rapidly progressive , lifethreatening metastasis , include symptomatic lymphangitic metastasis ) Symptomatic CNS disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Her2 negative</keyword>
	<keyword>Estrogen Receptor Positive</keyword>
	<keyword>Progesterone Receptor Positive</keyword>
	<keyword>MM-121</keyword>
	<keyword>Exemestane</keyword>
	<keyword>Postmenopausal Women</keyword>
</DOC>